Introduction
Cisplatin is an antitumor agent that is applied in the therapy of solid tumors, including testicular, ovarian and bladder cancer and head and neck squamous cell carcinoma (HNSCC). However, the response rates vary between tumor types. For HNSCC the complete and partial response rate is between 30% and 50%, without improvement of the long-term survival [1] . For testicular cancer the application of cisplatin-containing regimens has resulted in a disease-free survival of over 90% of patients [2, 3] . Because chemotherapy with cisplatin is accompanied by severe side effects [4] and because the tumor itself can be or can become resistant to cisplatin therapy, it is of interest to be able to determine the efficacy of the treatment already before the patient actually receives the drug. Unnecessary treatment could then be avoided and the dose and/or combination of the drug(s) adjusted. Such individualized drug administration could lead to improvement of response rates [5] and a better quality of life.
It is generally accepted that the antitumor activity of cisplatin results from its interaction with DNA, which leads to the formation of the so-called platinum (Pt)-DNA adducts [6, 7] . A limited number of different types of adducts are formed in DNA upon reaction with cisplatin: the monoadduct Pt-G and the diadducts Pt-GG (crosslink on pGpG sequences), Pt-AG (crosslink on pApG) and G-Pt-G (crosslink on pG[pX] n pG as well as interstrand crosslinks on two guanines) [7] . In the white blood cells (WBC) of patients with the same tumor type treated with cisplatin, large interindividual differences in DNA-adduct levels have been observed [5, [8] [9] [10] [11] [12] . These studies provided evidence, e.g., for ovarian cancer [13] that higher adduct levels in WBC correlate with a better clinical outcome. However, in breast cancer [13] and germ-cell tumors [14, 15] this correlation could not be confirmed.
A limited number of clinical studies tried to predict tumor response already prior to cisplatin treatment of the patient. Armstrong et al. [16] showed a correlation between adduct levels in in vitro cisplatin-treated bonemarrow cells and complete remissions in adult acute non-lymphocytic leukemia. Other studies have focussed on the relation between in vivo and in vitro DNA-adduct formation in WBC. Adduct levels in WBC of cisplatintreated testicular or non-small cell lung cancer patients (in vivo) appeared to correlate with those observed after in vitro cisplatin-treatment of WBC collected from these patients prior to chemotherapy [8, 17] .
No studies have been performed as yet on the tumor tissue itself to determine the possible correlation between in vivo-and in vitro -induced adduct formation and to use this to predict the clinical response. Previously, we reported on the in vivo-induced Pt-DNA adduct levels in human HNSCC xenografts in nude mice after cisplatin treatment [18] . A significant correlation was found between the tumor response in these mice and the amount ofPt-AGadducts.
In the present study, Pt-DNA adduct levels were determined after ex vivo cisplatin treatment of fragmented, isolated HNSCC tumors that had been grown as xenografts in nude mice. These data were compared with the in vivo -induced adduct levels and with the sensitivity parameters of these HNSCC xenografts. In addition, data are shown of the DNA-adduct levels in tumors of patients after ex vivo cisplatin-treatment of biopsy fragments. For this purpose, two tumor types with different sensitivities to cisplatin (HNSCC and testicular carcinoma) were investigated.
Materials and methods

Collection of tumors
Human HNSCC tumor lines (HNX-14C, -22B, -RO, -OE and -HN) were maintained in vivo by serial subcutaneous transplantations at both lateral sides in female, athymic, nude mice (6-8 weeks old; Harlan, Zeist, The Netherlands) as described earlier [18] . When the xenografts reached a volume of 100-200 mm 3 , mice were sacrificed and the tumors removed. The studies were performed after approval by the ethical committee at our Institute in accordance with the Dutch law on animal experiments.
Fresh HNSCC tissues were obtained from surgical specimens of eight patients. Testicular tumor tissues were obtained from eight patients who underwent orchidectomy. All patients provided signed informed consent according to local regulatory requirements. The tissues were kept at 4°C in Dulbecco's Modified Eagle's Medium (DMEM, Life Technologies [Gibco-BRL], Breda, The Netherlands) during transportation ( ^ 40 min) to the laboratory for further experiments.
Ex vivo cisplatin treatment HNSCC xenografts were treated with cisplatin (Platinol, Bristol-Myers Squibb, Woerden. The Netherlands) after dissection into tumor fragments. Attempts to use single cell suspensions obtained by enzymatic disruption were not successful, as this procedure yielded too many dead cells (data not shown).
For the treatment of tumor fragments, tumors were kept on ice and cut into pieces of 3 x 3 x 3 mm followed by exposure for one hour at 37 °C to various concentrations of cisplatin (0, 10, 20, 30, 40, 60 and 80 uM). The incubation time of one hour was chosen because after that time interval the correlation between adduct levels and a response was found to be maximal [18] ; thus the initial Pt-DNA adduct level is a measure of the Pt uptake. The cisplatin dilutions were freshly made in DMEM supplemented with 2.5% fetal calf serum (FCS). Subsequently, the tumor fragments were washed twice with PBS and with half of the fragments the incubation was prolonged in DMEM with 5% FCS but without the drug for 0 or 5 hours. After two washings with ice-cold PBS the tissue fragments were stored at -80 C. Experiments to determine Pt-DNA adducts (immunocytochemistry and 32 P-postlabeling) were performed at least in triplicate, i.e. with the tumors of three animals.
Tumors obtained from HNSCC and testicular carcinoma patients were treated with cisplatin (0 and 80 uM) according to the method described above for the tumor fragments. The concentration of 80 uM cisplatin was chosen because at that concentration the difference of adduct levels between a sensitive and the least sensitive tumor was maximal (see Figure 2 ). The testicular tumors were treated with the drug in the absence of FCS, because this influences the viability of the tumor cells [19, 20] . In these experiments also a drug-and serum-free incubation period of 18 hours was included. We have performed experiments to see whether the presence of FCS would influence the concentration of free Pt available for the cells. The amount of cisplatin available for binding (free cisplatin) appeared to be independent of the presence of FCS (data not shown).
Because of the small size of the tumor biopsies, often only single experiments were feasible and in case of HNSCC tumors, only the incubation with 80 uM cisplatin followed by the five-hour drug-free incubation was performed. The five-hour incubation period was chosen because it was expected to result in maximal DNA-adduct levels [21] .
In vivo cisplatin sensitivity
The determination of the response of the HNSCC xenografts to cisplatin therapy was described previously [22] . Briefly, when the tumors reached a volume of 50-200 mm 3 , the tumor-bearing nude mice were treated with cisplatin by intravenous injection, twice with a seven-day interval at the maximum tolerated dose of 7 mg/kg. The efficacy of the treatment was expressed as growth delay factor (GDF) of the tumor, defined as the difference between the median values of the time required by tumors of treated and control animals to double their volume, divided by the median value of the time required by the tumors of the control mice to double their volume [22] .
The outcome of cisplatin therapy was available only for three of the 16 patients from whom biopsies (prior to treatment) could be obtained, because only these three patients were treated with cisplatin. The relevant characteristics of all patients are listed in Table 1 . Two HNSCC Control 80 uM cisDlatin donated by Dr. M. Tilby, Newcastle-upon-Tyne, UK), which recognizes Pt-DNA adducts (1:1000 in TBS with 5% FCS and 0.05% Tween). The preparations were again washed in TBS (3 x 1 min) and incubated for one hour at 37 °C with rhodamine-labelled goat-antirabbit antibody (1:100 in TBS with 5% FCS; Kirkegaard & Perry Lab. Inc, Gaithersburg, MD, USA). The sections were then washed three more times and mounted with 0.4 ug/ml 4',6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma, St. Louis, MO, USA) in Tris-glycerol [1:3] , which stains all nucleated cells. The DNA adducts were visualized by fluorescence microscopy (Leitz Orthoplan, Heidelberg, Germany) or with scanning laser microscopy (Leica TCS 4D, Heidelberg, Germany).
Platinum-DNA adduct determination
In a previous study the intracellular Pt content significantly correlated with the sensitivity to cisplatin [18] . However, the Pt content cannot be determined in the patient tumor biopsies because these specimens are too small to allow detection with atomic absorptions spectroscopy. For this purpose, however, the sensitive postlabelling method can be used to measure Pt-DNA adducts [23] . With this newly developed method the major adducts formed upon cisplatin treatment, Pt-GG and Pt-AG, can be determined in small DNA samples with low platination levels, such as those derived from the ex vivo treated tumor fragments. Briefly, the isolated DNA was enzymatically digested to unmodified nucleosides and Pt-DNA adducts. Then, the adducts were purified on a strong cation-exchange column and 32 P-postlabelled after deplatination with NaCN and addition of an internal standard (dinucleotide TpT). The labeled products were separated by thin-layer chromatography and quantified by phosphorimaging (Phosphorlmager 425, Molecular Dynamics, Sunnyvale, CA, USA).
Statistics
Associations between variables were calculated by use of the Pearson correlation test. The correlation coefficients (r) of the mean values of each tumor line and two-sided significance levels were determined with the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA). A correlation with a /"-value of less than 0.05 was considered to be significant. Immunochemical staining of cisplatin-DNA adducts
Results
Cryostat sections (8 um thick) of untreated and cisplatin-treated tumor fragments were fixed with ice-cold (-20 °C) acetone for 10 min, followed by two 1-min washings with Tris-buffered saline (TBS; 20 mM Tris, 150 mM NaCl, pH 7.4). Then the cryostat sections were treated with Proteinase K. (0.5 ug/ml; Merck, Darmstadt, Germany) for 10 min at 37 °C, followed by washings with TBS for 1 min, 4 min and 1 min, respectively. The DNA was denatured by incubation with 0.07 M NaOH in TBS with 1% formaldehyde for 5 min at 37 °C, followed by 2 x 1 min TBS. The RNA was removed by RNAse treatment [100 ug RNAse A/ml (Sigma, St. Louis, MO, USA) in TBS] for one hour at 37 °C. After three washings in TBS the sections were preincubated for 20 min at 37 °C with 2% heat-inactivated fetal calf serum (FCS, Flow, Irvine, UK) in TBS, washed with TBS and incubated for one hour at 37 °C with the first antibody, ICR4 (kindly To investigate whether ex vi'vo-treatment of tumor xenograft fragments with cisplatin results in a homogeneous formation of DNA adducts across the whole fragment, the presence of adducts was visualized by immunocytochemical staining of a section through the centre of the fragment with the monoclonal antibody ICR4, directed against cisplatin-DNA adducts [24] . In Figure 1 , an example is shown of staining of HNX-22B tumor fragments. This homogenous staining of DNA-adducts in the whole fragment indicates that the conditions chosen in these experiments allow penetration of cisplatin and formation of DNA adducts throughout the whole tumor fragment.
DNA adducts after ex vivo cisplatin-treatment of fragments from HNSCC xenografts
The levels of the adducts Pt-AG and Pt-GG in the ex vivo cisplatin-treated HNSCC tumor fragments were determined by the 32 P-postlabelling assay. In Figure 2 , levels are shown that were obtained after a one-hour incubation with various concentrations of cisplatin with or without a five-hour additional incubation in drug-free medium. In general, the levels increased with the cisplatin concentration and were found to be higher after the five-hour drug-free incubation. As can be seen in Figure 2 , the data generally fit a linear curve. We argued that a suitable way to compare the adduct levels, which takes into account the results in the whole concentration range, was to calculate the slopes of the fitted lines. The relationships between these slopes (relative adduct levels) and the sensitivities of the tumors in vivo (expressed as GDF) [22] are given in Figure 3 . Immediately after the one-hour exposure period, significant correlations were found for the Pt-AG adduct (r = 0.92, P = 0.02) and for the Pt-GG adduct (r = 0.89, P = 0.03). After the drugfree incubation period, the correlations were no longer significant (r = 0.53, P = 0.34 for Pt-AG and r -0.52, P -0.35 for Pt-GG). In general, the correlations between the Pt-GG and Pt-AG levels in the DNA samples were significant, with and without the five-hour drugfree exposure (r = 0.99, P < 0.001; r = 0.98, P = 0.003, respectively).
To establish the relevance of the ex vivo data for the results on adduct levels obtained after in vivo cisplatin Figure 2 , and the AUC values over three-hour to three-day time period of the adduct levels (number of adducts/10 6 nucleotides x hour) formed in vivo in the HNSCC xenografts in nude mice as published elsewhere [18] . Pt-GG (•) and Pt-AG (o) adducts. treatment of the xenografts, the slopes of the lines in Figure 2 were compared with the area under the curve (AUC) of the adduct levels over the three-hour to threedays interval in cisplatin-treated xenografted mice [18] . The results given in Figure 4 show significant correlations (r = 0.92, P = 0.027 for Pt-GG; r = 0.97, P -0.007 for Pt-AG) between the in vivo data and those immediately after ex vivo treatment (Figure 4a) but not (r = 0.22, P -0.72 for Pt-GG; r = 0.36, P = 0.55 for Pt-AG) after the five-hour post-incubation period (Figure 4b ).
DNA adducts after ex vivo cisplatin treatment of tumor fragments from patients
The Pt-GG and Pt-AG adduct levels in ex v/vo-treated HNSCC and testicular tumors from patients were also drug-free period (h) Figure 5 . HNSCC and testicular tumor biopsies from untreated patients were incubated as 3 x 3 x 3 mm fragments with 80 uM of cisplatin for 1 hour, and subsequently incubated for 5-and/or 18-hour in drug-free medium. The Pt-AG and Pt-GG adduct levels (number of adducts/10 6 nucleotides) were determined by 32 P-postlabeling. The data for the tumors from patients of whom the response to cisplatin chemotherapy was available, are indicated as follows: testicular cancer: A -complete response; HNSCC: • -partial response and A -no response. The other patients did not receive cisplatin therapy. measured by 32 P-postlabelling. The data after incubation of tumor fragments for one hour with 80 uM of cisplatin followed by 5-hour and 18-hour drug-free incubation periods are depicted in Figure 5 and show that Pt-DNA adduct levels in the testicular tumors were comparable to those of the HNSCC tumors. In most of the eight testicular tumors the adduct levels were not decreased and even increased during the 5-to 18-hour drug-free period. Because most of the HNSCC biopsies were too small to perform analyses at several time points, no such conclusions can be drawn for this tumor type.
Two of the eight HNSCC patients were treated with cisplatin as a single drug and one testicular carcinoma patient was treated with a cisplatin-containing regimen ( Table 1 ). The tumor of one of these HNSCC patients showed a partial response and the other was unresponsive. The patient with the testicular cancer showed a complete response. The ex vivo -treatment of the tumors from the two HNSCC patients with 80 uM cisplatin followed by a five-hour drug-free incubation resulted in Pt-GG and Pt-AG adduct levels of 27.4 and 5.1 adducts/10 6 nucleotides, respectively, for the patient showing the partial response, and of 13.2 and 2.4 adducts/10 6 nucleotides, respectively, for the non-responder (see Figure 5 ). Also after an 18-hour drug-free incubation the levels in the more sensitive tumor were higher. The Pt-GG and Pt-AG adduct levels in the testicular carcinoma after the five-hour post-incubation were 22.9 and 10.4 adducts/10 6 nucleotides, respectively. For this patient a complete response was observed, i.e. he was considered free of disease.
Discussion
In our studies possible methodologies were investigated and optimized to predict the efficacy of cisplatin treatment already prior to the actual chemotherapy of patients with solid tumors. Because of the conflicting results on the relation between Pt-DNA adduct levels present in WBC and the response of patients upon the cisplatin treatment [5, [8] [9] [10] [11] [12] [13] [14] [15] , we decided to determine the adduct levels in the target tissue itself, i.e. in the tumor. As published elsewhere [18] , we found positive correlations between the response and the in vivo formed Pt-DNA adducts after cisplatin treatment of nude mice, in which HNSCC cells were grown as xenografts.
Since tumor biopsies are often taken from patients before chemotherapy starts, these specimens can be used in a test for predicting the possible outcome of the treatment. A priori culturing of these cells or explants has the disadvantage that it will take too much time. In addition, growth can be difficult to achieve as we experienced for human testicular tumors; after implantation in nude mice growth was only seen for twoout of six tumors. Another drawback of the use of cultured tumor cells for the prediction of the in vivo tumor response is the lack of correlation between results obtained after in vivo (in xenografts in mice) and in vitro (in the cultured cell lines) treatment of our panel of HNSCC cells [18] .
In the present study the relevance of an ex vivo cisplatin incubation of tumor fragments for the outcome of the in vivo treatment was investigated in HNSCCs grown as xenografts in nude mice. Because only small biopsies will become available from patients and to ensure optimal conditions for penetration of the drug, small fragments ( 3 x 3 x 3 mm) of the HNSCC tumors were used for this purpose. As shown in Figure 1 , despite the lack of blood circulation, the penetration of cisplatin into tumor fragments of this size appears to be fairly homogeneous.
The results on the Pt-GG and Pt-AG adduct levels after ex vivo cisplatin treatments of the HNSCCs (Figure 2 ) indicate that the levels increase linearly with the dose and that they are higher after a five-hour additional incubation in drug-free medium than immediately after the one-hour cisplatin treatment. This is in agreement with the findings of Fichtinger-Schepman et al. [21] that the conversion of cisplatin monoadducts to diadducts is complete after about five hours.
As shown in Figure 3 , immediately after the one-hour cisplatin treatment the Pt-AG and Pt-GG adduct levels were found to be correlated with the in vivo sensitivity of the tumor lines (r = 0.92, P = 0.02 for Pt-AG; r = 0.89, P = 0.03 for Pt-GG). However, after the five-hour additional incubation, such a correlation between sensitivity and adduct levels could not be found (r = 0.52, P = 0.35 for Pt-GG; r = 0.53, P = 0.34 for Pt-AG). The ex vivo levels after the one-hour exposure also correlated with the AUC values of the adducts in the tumors after in vivo treatment of the xenograft-bearing nude mice with r = 0.92, P = 0.027 for the Pt-GG and r = 0.97, P = 0.007 for the Pt-AG adduct (Figure 4) . Such a correlation was not found after the five-hour additional drug-free incubation period (r = 0.22, P = 0.72 for Pt-GG; r = 0.36, P = 0.55 for Pt-AG). This indicates that the overall outcome of the various processes that may be ongoing in the tumor tissue during the ex vivo drug-free period, e.g. DNA repair and cell death, is not related to the in vivo drug response.
In general, cisplatin-treated mammalian cells are able to remove their Pt-DNA-adducts by enzymatic DNArepair processes [27] [28] [29] . Therefore, to investigate the formation and persistence of the adducts in biopsies from patients, the ex vivo one-hour cisplatin-treated tumor fragments of some of the HNSCC and testicular carcinomas were also incubated for an additional period of 18 hours in drug-free medium.
Testicular carcinomas are much more sensitive to cisplatin than HNSCC [1] [2] [3] , however, as can be seen from Figure 5 , about the same levels of the DNA adducts are formed in both tumor types. In most of the testis samples the adduct levels did not decrease during the additional drug-free incubation period, indicating that (almost) no repair of the adducts had occurred. This is in agreement with published data for cultured cell lines [28, [30] [31] [32] . Unfortunately, due to the small size of the HNSCC biopsies, not enough information could be obtained for this tumor type to draw any conclusions about the persistence of the adducts.
Two of the HNSCC patients of whom biopsies were obtained, subsequently received cisplatin therapy, one showed a partial response and the other no response to the treatment. Only one of the testicular carcinoma patients was treated with cisplatin which resulted in a complete response (Table 1 ). The adduct levels in the ex vivo treated biopsies of the two HNSCC patients were in line with what could be expected on the basis of the tumor response: Pt-GG and Pt-AG levels were higher in the more sensitive tumor, after 5-hour as well as 18-hour drug-free incubation period. Because no data are available for the responder, no comparison of the data after the one-hour cisplatin incubation is possible.
In conclusion, the bifunctional Pt-DNA adduct levels (Pt-GG, Pt-AG) present after a one-hour ex vivo cisplatin treatment of fragments of human HNSCC tumors xenografted in nude mice were found to correlate with the response of these tumors when the tumor-bearing mice were treated with cisplatin in vivo, and with the AUC levels of the adducts measured after the in vivo treatments. With respect to the adduct levels immediately after the one-hour ex vivo treatment of tumor biopsies from patients hardly any differences between testicular cancer and HNSCC were observed. The limited data on adduct levels in the tumor tissue samples of two HNSCC patients were in line with the hypothesis that higher adduct levels are associated with a better clinical response.
